We’re hiring!
The Filbin lab is searching for a motivated wet-lab staff scientist, computational scientist, and research technician to help us fight for a cure to pediatric brain tumors. Our scientists would lead cutting-edge research in single-cell multiomics, spatial transcriptomics, and more, assisting in our efforts to understand how tumor cells shape-shift in response to intrinsic and extrinsic factors.
Application link for the above positions:
Wet-lab staff scientist
Computational scientist
Research technician
Also reach out to our lab admin James (jamesa_mclean@dfci.harvard.edu) for more information on all available positions.
The Filbin lab is searching for a motivated wet-lab staff scientist, computational scientist, and research technician to help us fight for a cure to pediatric brain tumors. Our scientists would lead cutting-edge research in single-cell multiomics, spatial transcriptomics, and more, assisting in our efforts to understand how tumor cells shape-shift in response to intrinsic and extrinsic factors.
Application link for the above positions:
Wet-lab staff scientist
Computational scientist
Research technician
Also reach out to our lab admin James (jamesa_mclean@dfci.harvard.edu) for more information on all available positions.
The Filbin Lab
Pediatric Neurooncology, Genomics and Technology
The Filbin Lab at the Dana-Farber Cancer Institute studies pediatric brain tumors, particularly the lethal high-grade gliomas including DMG and malignant embryonal brain tumors that are in greatest need of therapeutic improvements.
We are especially interested in how the specific developmental and cellular contexts in which tumorigenic mutations arise shape the cellular hierarchy of the resulting tumors. This developmental “fingerprint” can then be used to design novel therapies that either enable differentiation of tumor cells so they are no longer proliferating or induce tumor cell death.
In our studies we are combining single-cell genetics and transcriptomics with gene editing-, epigenetic-, stem cell- and pharmacologic methods to identify these cellular states, hierarchies and networks underlying tumorigenesis, with the goal of establishing new druggable targets.
We are especially interested in how the specific developmental and cellular contexts in which tumorigenic mutations arise shape the cellular hierarchy of the resulting tumors. This developmental “fingerprint” can then be used to design novel therapies that either enable differentiation of tumor cells so they are no longer proliferating or induce tumor cell death.
In our studies we are combining single-cell genetics and transcriptomics with gene editing-, epigenetic-, stem cell- and pharmacologic methods to identify these cellular states, hierarchies and networks underlying tumorigenesis, with the goal of establishing new druggable targets.
|
|
|
|